来源：智通财经 图片来源：视觉中国 智通财经记者 | 陈杨 智通财经编辑 | 许悦 | | corporate strategy Therapy area priorities | | | Portfolio focus | Investment approach | | --- | --- | --- | --- | --- | --- | | | Diabetes | Obesity | | Broad and deep | Key investment focus | | 2 | CVD | RBD | | Multiple targets in key segments | Invest to build competitive pipelines | | 3 | MASH | RED | CKD | Selective, based on potential and synergies | Targeted investment allocation | | 4 | | | | Opportunistic and trigger-based | Targeted investment allocat ...

In the pharmaceutical industry, companies often rely on raising prices on existing drugs to meet earnings targets. Lilly is doing the opposite. During the third quarter, the company’s revenue growth was driven by a 62% increase in sales volume, while realized prices for its products decreased by approximately 10%.The primary driver of Lilly’s trillion-dollar valuation is found in its third quarter 2025 earnings results. Total revenue reached $17.6 billion, a 54% increase from the same period the previous ye ...

for more on Novo and Pharmaceutical spring and Guggenheim's biotech analyst Sheamus Fernandez. Sheamus, your take on the Novo results. Uh yeah, so I guess it's not too surprising to the overall market uh what happened here.This was a high-risisk reward clinical study for Nova Nordisk. Um it was well communicated by the company that way. But that being said, uh the company has had a lot of challenges this year, largely from competition from Eli Liy, but it also faces pretty challenging year in 2026 and poten ...

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)Gado via Getty ImagesEli Lilly’s stock (NYSE: LLY) soared nearly 50%, in the past six months, driven not only by outstanding earnings and a notable margin increase, but also by reaching a $1T market cap and excitement surrounding revolutionary GLP-1 and oral drug potentials. Let’s explore the factors behind this extraordinary surge. Sep ...

November 23, 2025 11:31 PM GMT Eli Lilly & Co. | North America Obesity Medications: The Broadening – Where do we go from here? | What's Changed | | | | --- | --- | --- | | Eli Lilly & Co. (LLY.N) | From | To | | Price Target | $1,171.00 | $1,290.00 | Earlier this year we outlined our views on "The Broadening" of the GLP-1 market driven by a number of factors, which are playing out. We refresh our LLY model to incorporate these recent developments, in addition to insights from our physician survey; our PT go ...

November 24, 2025 12:22 AM GMT Biopharma | North America Primary Care Physician Outlook for oral GLP-1s We conducted a proprietary AlphaWise survey among ~200 US primary care physicians to glean insights into oral and injectable GLP-1 prescribing ahead of the potential launches of LLY's orforglipron and Novo's high-dose oral semaglutide in early 2026. M We expect the FDA to approve two new oral GLP-1 medicines for obesity over the near term - LLY's Orforglipron (1Q26) and Novo's high-dose oral Semaglutide ( ...

作者 | 武月 11月21日，礼来股价上涨1.59%，收于1059.70元/股，全球首家迈入"万亿美元俱乐部"的药企，也终于诞 生了。 一直以来，万亿美元市值是科技巨头的专属领地。2018年，苹果成为美股首家万亿美元的巨头，此后跟 进的8家企业中，6家均为科技公司，仅特斯拉与伯克希尔・哈撒韦两个 例外。 如今礼来的闯入，不仅再次改写了万亿市值俱乐部的行业构成，更彻底捅破了创新药行业的估值天花 板。 市场沸腾背后，是一场关于"价值逻辑"的重构。过去十年，创新药企的市值天花板被锚定在千亿美元， 国内在无数创新药企奋力攀爬，却始终难越雷池。 （来源：氨基观察） 转自：氨基观察 礼来的登顶证明，创新药的天花板，本质是想象力的天花板。当一款药物能撬动千亿美元市场、覆盖近 亿患者，传统估值模型便显得苍白。 并且，万亿美元并非终点。大多数达成这一里程碑的科技巨头，随后都实现了数万亿美元的市值。只不 过，专利周期的诅咒、技术迭代的焦虑、管线断层的风险……制药业的兴衰规律并未改变。 礼来用十年务实主义攀上巅峰，但这才是真正的试炼开端。 减肥药，推开万亿美元大门 礼来的万亿美元之路，始于一款GLP-1双靶点药物替尔泊肽。2023 ...

What have been your key takeaways from your India roll out so far, and which strategic calls have worked for you in this market?One of the most important aspects to look at is the unmet need in India. There are nearly 100 million people living with obesity and diabetes who can potentially benefit from this medication.Coming to the launch of tirzepatide, a couple of things account for the success we've had to date. The first is the product itself. Tirzepatide (Mounjaro) offers a dual mechanism—it is the firs ...

Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access to obesity medicines. Starting April 1, 2026, Medicare beneficiaries will not have to pay more than $50 per month for Zepbound (tirzepatide), which comes in a multi-dose pen, and for orforglipron, El ...

Financial Data and Key Metrics Changes - Consolidated revenue grew 13% year-over-year to $60.2 million, with telehealth revenue increasing 18% to $47.3 million [18][19] - Adjusted EBITDA increased 30% compared to the prior year, totaling $5.1 million for the third quarter [19][21] - Gross margin for the third quarter was 88%, a decline of 290 basis points year-over-year due to revenue mix [18][19] Business Line Data and Key Metrics Changes - The RexMD business added approximately 10,000 net new subscribers, rebounding from previous lows [4][17] - Weight management remains over 50% of the company's total revenue mix, although there was a slight sequential decline in subscriber base [24][25] - Demand for personalized ED medications represented 25% of all new ED prescriptions on the RexMD platform [10] Market Data and Key Metrics Changes - LifeMD is positioned to be a leading virtual destination for high-quality care, with over 130 million Americans eligible for treatment [9] - The company expects to offer oral GLP-1 medications, which could significantly broaden access and reshape the market landscape [9][56] Company Strategy and Development Direction - Strategic priorities for 2026 include accelerating growth in weight management, scaling women's and behavioral health businesses, and launching a unified LifeMD platform [6][15] - The company aims to leverage collaborations with Novo Nordisk and Eli Lilly to enhance its competitive advantage in the GLP-1 space [7][8] - LifeMD plans to invest in growth for women's health and behavioral health offerings, which are expected to become significant revenue streams [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, anticipating significant growth driven by better pricing for branded therapies and increased insurance coverage [28][34] - The competitive landscape in the weight management category has intensified, but LifeMD remains focused on high-quality offerings [7][56] - The anticipated approval of the Wegovy pill is expected to be a major catalyst for business growth [9][56] Other Important Information - The company divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to focus on its core healthcare platform [5][17] - LifeMD has secured regulatory approval for its non-sterile 503A compounding pharmacy, which will enhance its ability to produce personalized medications [5][11] Q&A Session Summary Question: Can you talk about the mix of telehealth product revenue, especially in weight loss? - Weight management still constitutes more than 50% of total revenue, with a slight sequential decline in subscriber base [24][25] Question: What portion of your revenue is insurance-covered versus cash-pay? - Management is not prepared to provide an exact percentage but noted that a significant portion of patients do not continue due to lack of insurance coverage [34][37] Question: How much of the growth in RexMD is driven by men's HRT versus ED? - About 8,000 of the 10,000 new members came from the sexual health business, primarily ED [61] Question: What drove the decline in telehealth gross margin? - The decline was attributed to a shift towards branded products, which do not carry the same fulfillment fees as personalized compounds [62][63] Question: What impact do you expect from the new consumer-facing app and website? - The new app is expected to significantly enhance cross-selling ability and improve customer retention [75][76] Question: What is the anticipated timeline for reaching 50-state coverage for the 503A pharmacy? - The company expects to be licensed in 35 states within 60-90 days and aims for full coverage shortly thereafter [80][81]